How to Get Wegovy at a Discount in 2026: What Actually Works

Last Updated: March 2026

Wegovy, the once-weekly semaglutide injection, has fundamentally reshaped the landscape of weight management. In the pivotal STEP 1 clinical trial, participants receiving semaglutide achieved a mean weight loss of 14.9% from baseline, significantly outperforming the 2.4% observed in the placebo group over 68 weeks (Wilding et al., 2021). This efficacy comes with a considerable price tag, often exceeding $1,300 per month without insurance coverage. For many, accessing this life-changing medication hinges on finding viable cost reduction strategies. The good news is that as of 2026, several legitimate avenues exist to secure Wegovy at a substantial discount.

Novo Nordisk’s Official Savings Programs: Manufacturer-Direct Discounts

The most direct route to savings often originates from the manufacturer itself. Novo Nordisk, the maker of Wegovy, has proactively implemented programs designed to make the medication more accessible, especially for those without insurance coverage or whose plans do not cover GLP-1 agonists for weight loss.

New Patient Introductory Offer

In a significant move to broaden access, Novo Nordisk initiated a special introductory offer. As reported by Pharmaceutical Commerce in October 2025, new self-pay patients can obtain Wegovy (and Ozempic) for $199 per month until March 31, 2026 (Pharmaceutical Commerce, 2025). This program targets individuals initiating treatment and offers substantial savings compared to the standard list price. This is a limited-time offer, and eligibility criteria typically apply, such as being a new patient to the medication and paying cash.

Price Reduction for Uninsured Patients

Beyond introductory offers, Novo Nordisk announced a substantial 23% price reduction for uninsured patients in March 2025. This adjustment lowered the monthly cost of Wegovy from approximately $650 to $349 for those paying out-of-pocket. This move directly addresses a significant barrier for a segment of the population previously unable to afford the medication.

NovoCare® and Savings Cards

Novo Nordisk also operates the NovoCare® program, which includes patient assistance programs and savings cards. These programs are designed to help eligible patients reduce their out-of-pocket costs. While specific terms can vary, some savings cards have been reported to bring copays down to as low as $25 per month for eligible patients, often covering up to $150 per month in savings (Novo Nordisk, 2026). It’s crucial for patients to check the specific eligibility requirements for these cards, which often include commercial insurance coverage and a cap on total annual savings.

Telehealth Platforms and Bundled Care Discounts

The rise of telehealth has introduced new models for medication access, sometimes including discounted pricing. These platforms often streamline the prescription process and, in some cases, negotiate bulk purchasing or provide integrated care packages that lower overall costs.

Some telehealth providers offer monthly subscriptions that include consultations, prescription management, and in certain instances, access to discounted medication pricing through their network of pharmacies or direct fulfillment. While specific “telehealth discounts” on Wegovy itself might be less common than direct manufacturer offers, the convenience and potential for bundled services can still result in overall savings. Patients should inquire directly with telehealth platforms about their medication pricing strategies and if they integrate any manufacturer savings programs.

Pharmacy Discount Programs: GoodRx and Beyond

Pharmacy discount services like GoodRx have become a staple for many looking to reduce medication costs. These platforms aggregate pricing from various pharmacies, allowing patients to compare and select the most affordable option.

GoodRx has reported offering Wegovy coupons for uninsured patients in 2026, with prices ranging from $149 to $349 per month. A key point to note is that these lower prices, particularly the $149/month offer, may be specific to lower doses of Wegovy and might have an expiration date, such as April 2026, as previously observed in reports related to GoodRx’s offerings. It’s important to understand that Wegovy is an injectable medication, not an oral pill, and GoodRx coupons would apply to the injection pens. These programs require patients to search for coupons in their local area and present them at participating pharmacies.

FH.co: A Legitimate Pathway to Discounted Access

Navigating the various discount programs can be complex. Services like FH.co specialize in connecting patients with legitimate savings opportunities for medications like Wegovy. FH.co acts as an intermediary, streamlining the process of identifying and accessing manufacturer programs, pharmacy discounts, and other legitimate savings avenues.

FH.co aims to simplify the often-confusing landscape of drug pricing. By leveraging their network and expertise, they can guide patients to programs that fit their specific eligibility criteria, whether it’s a manufacturer’s savings card, a patient assistance program, or a pharmacy-specific discount. This can be particularly beneficial for those who find the application processes for individual programs daunting or time-consuming.

Ready to explore your Wegovy savings options? Visit FH.co to find out how you can access discounts for Wegovy and potentially reduce your monthly costs: Explore Wegovy Discounts via FH.co

Comparing Wegovy Discount Avenues (2026 Estimates)

Note: Prices are estimates based on reported programs and can vary based on individual eligibility, location, pharmacy, and program terms.

Navigating the Process

Successfully obtaining Wegovy at a reduced cost requires proactive engagement. Here’s a brief guide:

1. Confirm Eligibility: Each program has specific criteria. Check if you meet the requirements for commercial insurance, income levels, or new patient status.
2. Gather Information: Be prepared with your prescription details, insurance information (if applicable), and personal identification.
3. Compare Options: Use tools like FH.co or GoodRx to compare prices from different pharmacies and evaluate manufacturer programs.
4. Stay Informed: Program terms, prices, and availability can change. Continuously monitor updates from Novo Nordisk and other discount providers.

“The substantial list price of GLP-1 receptor agonists presents a significant barrier to access for many patients with obesity,” notes the FDA’s original approval documents, underscoring the ongoing challenge of affordability for effective treatments (U.S. Food and Drug Administration, 2021). By leveraging the available programs and resources, patients can significantly reduce their financial burden and access the care they need. The landscape of Wegovy discounts in 2026 offers multiple legitimate pathways for savings, empowering patients to make informed decisions about their treatment costs.

Sources

1. Wilding, J. P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicine, vol. 384, no. 11, 2021, pp. 989-1002.
2. “Wegovy (semaglutide) injection, for subcutaneous use.” U.S. Food and Drug Administration, 4 June 2021, www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf.
3. “Novo Nordisk Rolls Out $199 Intro Offer for Wegovy and Ozempic, Months Ahead of Planned Price Cuts.” Pharmaceutical Commerce, 24 Oct. 2025, www.pharmaceuticalcommerce.com/view/novo-nordisk-rolls-out-intro-offer-for-wegovy-and-ozempic-.
4. Novo Nordisk US. “NovoCare®.” www.novocare.com/ (Accessed March 2026).